CARA (caratherapeutics.com) Net Income

Official company branding of Cara Therapeutics Inc. (CARA)

A fabless model utilizing outsourced molecule synthesis is combined with rigorous crisis management by leadership. The net profit trend for Cara Therapeutics, Inc. (CARA) on this chart on GURU.Markets shows that -0.03 represents the latest metric reading. The financial stability of Cara Therapeutics, Inc. (CARA) is based on licensing payments for anti-pruritic drugs, which ensures a moderate predictability of cash flows.

Cara Therapeutics Inc (CARA) Company Net Income: for the period 07/04/2022 - 11/01/2026

Comprehensive metric breakdowns and analytics for Cara Therapeutics (CARA)

- stock value and consensus price forecast:
Market Price Cara Therapeutics Inc|CARA - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Cara Therapeutics Inc|CARA - Enterprise Value
- company book value details:
Book Value per Share Cara Therapeutics|CARA - Company Book Value|Market Value to Book Value caratherapeutics.com|CARA - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Capital Cara Therapeutics, Inc.|CARA - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Cara Therapeutics Inc.|CARA - Company Total Debt|Debt to Book Capital Cara Therapeutics Inc|CARA - Company Long-Term Debts|Company Short-Term Loans and Borrowings Cara Therapeutics|Immediate Liquidity caratherapeutics.com
- earnings and market multiples details:
CARA - Company Net Income
Summary company analysis:Cara Therapeutics Inc - CARA
Manufactured product of Cara Therapeutics Inc.

The financial results of Cara Therapeutics, Inc. (CARA) depend directly on the commercialization of anti-pruritic drugs and licensing payments from partners. This indicator captures the remaining funds after deducting all operating expenses and taxes, allowing investors to distinguish the real value of the business from speculative expectations. Analyzing the net income trend of the company helps identify the risk of capital burn in a timely manner or confirm the effectiveness of developing new molecules.

Direct competitors

Company Net Income Biogen Idec (BIIB)|NBIX (Neurocrine Biosciences) - Net Profit|Net Income regencellbioscience.com (RGC)|Net Profit AXSM|Net Profit ACADIA Pharma (ACAD)|Company Net Income Xenon Pharmaceuticals Inc XENE|Final Profit VKTX|Supernus Pharmaceuticals - Net Profit|CPRX - Net Profit|DNLI (Denali Therapeutics Inc.) - Net Income|Harmony Biosciences Inc - Final Profit|Net Income BHVN|AMLX (Amylyx Corp) - Profit After Payment of Taxes|Net Profit TRVI|PRAX (praxismedicines.com) - Final Profit|Net Profit AVXL (Anavex Life Sciences Corp.)|CeriBell Inc (CBLL) - Company Net Income|PRTA - Company Net Income|Final Profit ALEC (Alector, Inc.)|ANNX: Net Profit|Omeros (OMER) - Net Profit|Company Net Income Neurogene|AC Immune S.A. - Profit After Tax|Net Profit VYGR|NMRA - Company Net Income|Scilex Holding Company - Net Income|Net Profit tevogen.com TVGN|ACOG: Net Income|cogrx.com - Profit After Payment of Taxes|IKT: Net Profit|SAVA - Net Financial Result|ASRT (Assertio Holdings) - Net Profit|Net Income Coya (COYA)|Company Net Income Vistagen Therapeutics (VTGN)|Net Financial Result ovidrx.com|Acumen Pharma - Net Income|Final Profit CRVO|Alterity Therapeutics Ltd - Net Profit|Net Financial Result Clene Inc. CLNN|pepgen.com (PEPG) - Company Net Income|Company Profit JUNS|RLMD (Relmada) - Net Profit|Net Income Annovis Bio Corporation (ANVS)|Net Income GRCE (Grace Therapeutics, Inc.)|Net Financial Result fireflyneuro.com|Net Profit KLTO (Klotho Neurosciences)|NRSN - Net Income|Reviva Pharmaceuticals Holdings - Net Profit|MTVA - Net Profit|NeurAxis, Inc. (NRXS) - Company Net Income|Helius Medical Technologies - Final Profit|PASG (Passage Bio Inc.) - Net Profit|Net Profit Neuphoria|Company Net Income Minerva Neurosciences Corp (NERV)|Athira Pharma Corp - Company Profit|Net Profit ADXN (Addex Therapeutics)|Alzamend Neuro Inc. (ALZN) - Company Net Income|CYCN: Net Income|PTIX - Net Profit|pasitheaclinics.com (KTTA) - Company Net Income|Cortigent - Final Profit|Company Net Income Avenue Therapeutics|Company Net Income brainstorm-cell.com BCLI|Net Profit CHRO|Net Income eliemtx.com ELYM|Net Profit ITCI (Intra-Cellular Therapies, Inc.)|Net Profit Longboard LBPH|MRNS - Company Net Income|Final Profit NKGN (nkgenbiotech.com)|NRBO: Net Profit|Sage Therapeutics Inc. (SAGE) - Net Profit|Net Income SNPX|TRVN: Final Profit|Net Income VIGL (Vigil Neuroscience)|Profit After Payment of Taxes WENA|Net Profit CERE (Cerevel Therapeutics, Inc.)